Can we prevent psoriatic arthritis? PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO. https://t.co/03H4YrvxMe https://t.co/efUVaccSHn

• Can we prevent psoriatic arthritis? | RheumNow

Is Izokibep the new kid on the block in PsA? ➡️ IL-17A inhibitor ➡️ Complete resolution of enthesitis at 16w ➡️ Overall good safety data LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG

• https://twitter.com/DrMiniDey/status/1801953990738890831/photo/1
• https://twitter.com/DrMiniDey/status/1801953990738890831/photo/1
• https://twitter.com/DrMiniDey/status/1801953990738890831/photo/1

RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

EULAR Abstract Archive RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX) 870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

EULAR Abstract Archive OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024

• EULAR Abstract Archive